Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Rhea-AI Summary
Q32 Bio (Nasdaq: QTTB), a clinical stage biotechnology company developing biologic therapeutics for immune homeostasis, has announced its upcoming participation in Guggenheim's Inaugural Healthcare Innovation Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 10:00 a.m. E.T. in Boston, MA. The presentation will be accessible via webcast on Q32 Bio's website, with replays available for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, QTTB gained 1.88%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase 2 trials for the treatment of atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has completed a first-in-human, Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-guggenheims-inaugural-healthcare-innovation-conference-302295851.html
SOURCE Q32 Bio
FAQ
When is Q32 Bio (QTTB) presenting at Guggenheim's Healthcare Innovation Conference 2024?
How long will Q32 Bio's (QTTB) Guggenheim Conference presentation replay be available?
Where can I watch Q32 Bio's (QTTB) Guggenheim Conference presentation?
What type of event will Q32 Bio (QTTB) participate in at the Guggenheim Conference?
